Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
10.55
+1.27 (13.69%)
At close: Aug 14, 2026, 4:00 PM EDT
10.45
-0.11 (-1.00%)
After-hours: Aug 14, 2026, 4:24 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
655.77M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Autolus Therapeutics | 117.39M |
| ARS Pharmaceuticals | 116.93M |
| Verastem | 87.53M |
| Assembly Biosciences | 74.85M |
| Prelude Therapeutics | 22.42M |
| Prime Medicine | 4.07M |
| Artiva Biotherapeutics | 251.00K |
SGMT News
- 1 day ago - Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients - GlobeNewsWire
- 3 days ago - Sagimet Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 3 days ago - Sagimet Biosciences Quarterly report: Q2 2026 - Filings
- 3 days ago - Sagimet Biosciences Earnings release: Q2 2026 - Filings
- 10 days ago - Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference - GlobeNewsWire
- 6 weeks ago - Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes - TheFly
- 6 weeks ago - Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 7 weeks ago - Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire